Boron chemicals in diagnosis and therapeutics
Advances in the field of boron chemistry have expanded the application of boron from
material use to medicine. Boron-based drugs represent a new class of molecules that …
material use to medicine. Boron-based drugs represent a new class of molecules that …
Triple-negative breast cancer: new perspectives for targeted therapies
F Tomao, A Papa, E Zaccarelli, L Rossi… - OncoTargets and …, 2015 - Taylor & Francis
Breast cancer is a heterogeneous disease, encompassing a large number of entities
showing different morphological features and having clinical behaviors. It has became …
showing different morphological features and having clinical behaviors. It has became …
Graph convolutional networks for drug response prediction
Background: Drug response prediction is an important problem in computational
personalized medicine. Many machine-learning-based methods, especially deep learning …
personalized medicine. Many machine-learning-based methods, especially deep learning …
Nrf2-and ATF4-dependent upregulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibition
P Ye, J Mimura, T Okada, H Sato, T Liu… - … and cellular biology, 2014 - Am Soc Microbiol
The ubiquitin-proteasome pathway degrades ubiquitinated proteins to remove damaged or
misfolded protein and thus plays an important role in the maintenance of many important …
misfolded protein and thus plays an important role in the maintenance of many important …
The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib
M Milani, T Rzymski, HR Mellor, L Pike, A Bottini… - Cancer research, 2009 - AACR
The ubiquitin-proteasome system plays a key regulatory role in cellular homeostasis. The
inhibition of the 26S proteasome by Bortezomib leads to the accumulation of misfolded …
inhibition of the 26S proteasome by Bortezomib leads to the accumulation of misfolded …
Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells
CD Befani, PJ Vlachostergios, E Hatzidaki… - Journal of molecular …, 2012 - Springer
Bortezomib represents the first proteasome inhibitor (PI) with demonstrated antitumor activity
in the clinical setting, particularly for treatment of hematological malignancies. At the …
in the clinical setting, particularly for treatment of hematological malignancies. At the …
Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation
C Kao, A Chao, CL Tsai, WC Chuang, WP Huang… - Cell death & …, 2014 - nature.com
The antitumor activity of an inhibitor of 26S proteasome bortezomib (Velcade) has been
observed in various malignancies, including colon cancer, prostate cancer, breast cancer …
observed in various malignancies, including colon cancer, prostate cancer, breast cancer …
The chemotherapeutic agent bortezomib induces the formation of stress granules
MJ Fournier, C Gareau, R Mazroui - Cancer cell international, 2010 - Springer
Abstract Background Cytoplasmic stress granules (SGs) are specialized storage sites of
untranslated mRNAs whose formation occurs under different stress conditions and is often …
untranslated mRNAs whose formation occurs under different stress conditions and is often …
CIP2A is a target of bortezomib in human triple negative breast cancer cells
Introduction Triple negative breast cancer (TNBC) is very aggressive and currently has no
specific therapeutic targets, such as hormone receptors or human epidermal growth factor …
specific therapeutic targets, such as hormone receptors or human epidermal growth factor …
Emerging drug development technologies targeting ubiquitination for cancer therapeutics
Abstract Development of effective cancer therapeutic strategies relies on our ability to
interfere with cellular processes that are dysregulated in tumors. Given the essential role of …
interfere with cellular processes that are dysregulated in tumors. Given the essential role of …